

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

PROPOSED SHARE PREMIUM REDUCTION

As stated in the announcement of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated May 14, 2026 relating to the annual results of the Group for the year ended March 31, 2026, the Board recommends the Distribution by way of payment of the Final Dividend (for the year ended March 31, 2025: nil) and the Special Dividend (for the year ended March 31, 2025: nil) to the Shareholders whose names appear on the register of members of the Company at the close of business on the Dividend Record Date, subject to approval by the Shareholders at the Annual General Meeting.

PROPOSED SHARE PREMIUM REDUCTION

As the Company had insufficient contributed surplus available for distribution to the Shareholders as at March 31, 2026, the Distribution by way of the Final Dividend and the Special Dividend is intended to be funded through reduction of certain amount standing to the credit of the Share Premium Account and crediting of such amount to the Contributed Surplus Account in accordance with the provisions of the applicable laws of Bermuda.

The Board intends to put forward a proposal to the Shareholders at the Annual General Meeting pursuant to the laws of Bermuda and the Bye-Laws. As at March 31, 2026, the amount standing to the credit of the Share Premium Account was approximately RMB51,686,866,000 and the amount of accumulated losses of the Company was approximately RMB1,177,962,000. It is proposed that an amount of approximately RMB10,000,000,000 standing to the credit of the Share Premium Account be reduced, with the credits arising therefrom be credited to the Contributed Surplus Account, and to apply such amount standing to the credit of the Contributed Surplus Account in the

manner permitted by the Bye-Laws and all applicable laws of Bermuda, including offsetting accumulated loss of the Company or making distribution out of the Contributed Surplus Account to the Shareholders.

The Proposed Share Premium Reduction will be subject to the Shareholders' approval by way of a special resolution proposed to be passed at the Annual General Meeting and subject to the conditions set out in the section headed "Conditions of the Proposed Share Premium Reduction".

Reasons for the Proposed Share Premium Reduction

Pursuant to the Companies Act and the Bye-Laws, subject to the Solvency Test, the Company may pay dividends or make distributions to its members out of Contributed Surplus Account. The Proposed Share Premium Reduction and the subsequent transfer of the credit arising therefrom to the Contributed Surplus Account will therefore increase the distributable reserves of the Company, thereby enhancing the flexibility of future dividend distributions in accordance with the applicable laws of Bermuda.

The Board considers that it is in the interest of the Company and the Shareholders as a whole to implement the Proposed Share Premium Reduction.

Effects of the Proposed Share Premium Reduction

The implementation of the Proposed Share Premium Reduction does not involve any reduction in (i) the authorized or issued share capital of the Company or (ii) the nominal value of the Shares and will not affect the trading arrangements concerning the Shares. Save for the expenses to be incurred by the Company in relation to the Proposed Share Premium Reduction, the Board considers that the implementation of the Proposed Share Premium Reduction will not, in itself, have any material adverse effect on the underlying assets, liabilities, business operations, management or financial position of the Company or the interests of the Shareholders as a whole.

The Directors are of the view that there are no reasonable grounds for believing that the Company is, or after the Proposed Share Premium Reduction becoming effective would be, unable to pay its liabilities as they become due.

In view of the above, the Directors consider that the Proposed Share Premium Reduction is beneficial to the Company and its Shareholders as a whole.

Conditions of the Proposed Share Premium Reduction

The Proposed Share Premium Reduction is conditional upon the following being fulfilled:

- (i) the passing of a special resolution by the Shareholders to approve the Proposed Share Premium Reduction at the Annual General Meeting;

- (ii) the compliance with the requirements under section 46 of the Companies Act to effect the Proposed Share Premium Reduction; and
- (iii) the Directors having satisfied themselves that the Company is and after making the Distribution, there are reasonable grounds for believing that the Company is not, and after the payment would not be, unable to pay its liabilities as they become due.

Subject to the fulfillment of the above conditions, it is expected that the Proposed Share Premium Reduction shall become effective on the first business day immediately following the date of passing of the special resolution to approve the Proposed Share Premium Reduction at the Annual General Meeting; or upon the day on which the requirements of section 46 of the Companies Act are fulfilled (whichever is later).

GENERAL

A circular containing, among other things, the details of the Proposed Share Premium Reduction, a notice convening the Annual General Meeting and the relevant proxy form will be despatched to the Shareholders in due course in accordance with the Listing Rules.

Shareholders and potential investors of the Company should note that the Proposed Share Premium Reduction is conditional upon satisfaction of the conditions set out in this announcement and may or may not proceed. Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the Shares.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions have the following meanings:

“Annual General Meeting”	the forthcoming annual general meeting of the Company expected to be held on or around Friday, August 7, 2026 or such other dates to be announced in the circular, for approving, among other things, the Proposed Share Premium Reduction and the transferring of the credit arising therefrom to the Contributed Surplus Account
“Board”	the board of Directors
“Bye-Laws”	the bye-laws of the Company currently in force
“Companies Act”	the Companies Act 1981 of Bermuda, as amended from time to time
“Company”	Alibaba Health Information Technology Limited, a company incorporated in Bermuda, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 00241)

“Contributed Surplus Account”	the contributed surplus account of the Company within the meaning of the Companies Act
“Director(s)”	the director(s) of the Company
“Distribution”	a distribution by the Company to its Shareholders out of its contributed surplus account, by way of declaration and payment of the Special Dividend and the Final Dividend
“Dividend Record Date”	Thursday, August 13, 2026, being the record date for the determination of entitlement of the Shareholders to the Distribution by way of declaration and payment of the Final Dividend and the Special Dividend
“Effective Date”	the date on which the Proposed Share Premium Reduction shall become effective, being the first business day immediately following the date of the Annual General Meeting at which the relevant special resolution approving the Proposed Share Premium Reduction will be considered and, if thought fit, passed by the Shareholders; or upon the day on which the requirements of section 46 of the Companies Act are fulfilled (whichever is later)
“Final Dividend”	the proposed final dividend of RMB5.95 cents per Share in cash for the year ended March 31, 2026 to the Shareholders whose names appear on the register of members of the Company on the Dividend Record Date
“Group”	the Company and its subsidiaries
“HK\$” or “HKD”	Hong Kong dollar, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China, which, for the purpose of this announcement, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan

“Proposed Share Premium Reduction”	the proposed reduction of the amount of RMB10,000,000,000 standing to the credit of the Share Premium Account as at the Effective Date with the credit arising therefrom to be transferred to the Contributed Surplus Account and be applied in such manner as permitted under the laws of Bermuda and the Bye-Laws
“RMB”	Renminbi, the lawful currency of the PRC
“Share(s)”	ordinary share(s) in the issued capital of the Company with a nominal value of HK\$0.01 each
“Share Premium Account”	the share premium account of the Company
“Shareholder(s)”	the holders of the Shares
“Solvency Test”	(a) the Company is, and after making the Distribution would be, able to pay its liabilities as they become due; and (b) the realizable value of the Company’s assets would not thereby be less than the aggregate of its liabilities, its issued share capital and its share premium accounts
“Special Dividend”	the proposed special dividend of RMB13.52 cents per Share in cash for the year ended March 31, 2026 to the Shareholders whose names appear on the register of members of the Company on the Dividend Record Date
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

For and on behalf of the Board
Alibaba Health Information Technology Limited
Shen Difan
Chairman and Chief Executive Officer

Hong Kong, May 14, 2026

As at the date of this announcement, the Board comprises Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao and Mr. Xu Haipeng as the non-executive Directors; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.